Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., . . . Holman, R. R. (2019). Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial. Cardiovasc Diabetol.
Citação norma ChicagoClegg, Lindsay E., et al. "Effects of Exenatide and Open-label SGLT2 Inhibitor Treatment, Given in Parallel or Sequentially, On Mortality and Cardiovascular and Renal Outcomes in Type 2 Diabetes: Insights From the EXSCEL Trial." Cardiovasc Diabetol 2019.
MLA citiranjeClegg, Lindsay E., et al. "Effects of Exenatide and Open-label SGLT2 Inhibitor Treatment, Given in Parallel or Sequentially, On Mortality and Cardiovascular and Renal Outcomes in Type 2 Diabetes: Insights From the EXSCEL Trial." Cardiovasc Diabetol 2019.